Loading clinical trials...

Endothelin-1 Receptor Blockade in Resistant Hypertension | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Endothelin-1 Receptor Blockade in Resistant Hypertension

VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION

NCT04388124•University Hospital, Rouen

Summary

The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age between 30 and 80 years old
•Patients with resistant hypertension defined according to the criteria recognized by the French Society of Hypertension (SFHTA): arterial pressure greater than or equal to 140 and / 90 mm Hg under triple antihypertensive therapy at optimal dose comprising at least one diuretic pendant at less than 4 weeks.
•Patients with resistant hypertension confirmed by self-measurement (≥135 / 85 mmHg on average) or by ambulatory blood pressure measurement (mean of 24h ≥130 / 80 mmHg).
•Hemoglobin level ≥ 12 g / dL
•For women of childbearing potential, reliable methods of contraception (as defined by the WHO-Pearl Index) should be used (hormonal contraception should not be the only contraceptive method used during bosentan treatment).
•For postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months and age greater than 45, before the inclusion visit)
•Patient who read and understood the newsletter and signed the consent form
•Patient affiliated to a social security scheme

Exclusion Criteria

•Patients with hypertension
•Patients with secondary arterial hypertension other than sleep apnea syndrome or chronic renal failure stage 2 or 3.
•Patients with hypertension greater than or equal to 180 and / or 110mmHg
•Chronic renal failure stage 4 and 5 (defined by DFG CKD-EPI \<30 ml / min / 1,73m²)
•Renal transplant patient XML File Identifier: CEyMau8sPo+QFyOLD1ZEY3ZGFow= Page 11/22
•Orthostatic hypotension (decreased SBP\> 20mmHg and / or DBP\> 10mmHg occurring within 3 minutes of standing).
•Contra-indication to NATISPRAY 0.30 mg / dose, oral spray solution (including nitrate hypersensitivity) in accordance with the NATISPRAY
•SPC:
•shock, severe hypotension,
•in combination with sildenafil
+12 more criteria

Locations (1)

Chu Rouen

Rouen, France

Key Dates

Start Date

October 20, 2021

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

February 17, 2026

Enrollment

ESTIMATED participants

Conditions

Resistant Hypertension

Interventions

Bosentan

DRUG

Placebo

DRUG

Symplicity China Study

NCT07081243

Resistant Hypertension

View study

RECRUITINGPHASE2

Endocalyx in Treatment Resistent Hypertension

NCT06940011

Treatment Resistant Hypertension

View study

RECRUITINGNA

Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension

NCT06515795

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Endothelin-1 Receptor Blockade in Resistant Hypertension

Inclusion Criteria

Exclusion Criteria

Symplicity China Study

Endocalyx in Treatment Resistent Hypertension

Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension